Table 1.
Baseline and postoperative characteristics of the SMA and SSA groups.
| Characteristics | Participants, No. (%) | ||||
|---|---|---|---|---|---|
| All (n = 130) | SMA (n = 130) | SSA (n = 129) | P-value | ||
| Age, year | 0.73 | ||||
| ≤65 | 168 (64.9) | 83 (63.8) | 85 (65.9) | ||
| >65 | 91 (35.1) | 47 (36.2) | 44 (34.1) | ||
| Sex | 0.82 | ||||
| Female | 84 (32.4) | 43 (33.1) | 41 (31.8) | ||
| Male | 175 (67.6) | 87 (66.9) | 88 (68.2) | ||
| BMI, kg/m2 | 0.85 | ||||
| ≤25 | 206 (79.5) | 104 (80.0) | 102 (79.1) | ||
| >25 | 53 (20.5) | 26 (20.0) | 27 (20.9) | ||
| ECOG | 0.89 | ||||
| 0 | 214 (82.6) | 107 (82.3) | 107 (82.9) | ||
| 1 | 45 (17.4) | 23 (17.7) | 22 (17.1) | ||
| Tumor location | 0.53 | ||||
| Lower | 143(55.2) | 71(55.4) | 71(55.0) | ||
| Middle | 68(26.3) | 31(31.8) | 37(28.7) | ||
| Upper | 48(18.5) | 27(20.8) | 21(16.3) | ||
| Tumor size, cm | 0.27 | ||||
| ≤4 | 158 (79.2) | 75 (57.7) | 46 (64.3) | ||
| >4 | 101 (20.8) | 55 (42.3) | 83 (35.7) | ||
| Type of gastrectomy | 0.50 | ||||
| Total | 123 (47.5) | 59 (45.4) | 64 (49.6) | ||
| Distal | 136 (52.5) | 71 (54.6) | 65 (50.4) | ||
| Type of reconstruction | 0.24 | ||||
| Billroth I | 15 (5.8) | 5 (3.8) | 10 (7.8) | ||
| Billroth II | 121 (46.7) | 66 (50.8) | 55 (42.6) | ||
| Roux-en-Y | 123 (47.5) | 59 (45.4) | 64 (49.6) | ||
| Pathological type | 0.76 | ||||
| Undifferentiated | 147 (56.8) | 75 (57.7) | 72 (55.8) | ||
| Differentiated | 112 (43.2) | 55 (42.3) | 57 (44.2) | ||
| cT stage (AJCC8th) | 0.87 | ||||
| T1 | 87 (33.6) | 41 (31.5) | 46 (35.6) | ||
| T2 | 35 (13.5) | 19 (14.6) | 16 (12.4) | ||
| T3 | 84 (32.4) | 42 (32.4) | 42 (32.6) | ||
| T4a/T4b | 53 (20.5) | 28 (21.5) | 25 (19.4) | ||
| cN stage (AJCC8th) | 0.50 | ||||
| N0 | 109 (42.1) | 52 (40.0) | 57 (44.2) | ||
| N + | 150 (57.9) | 78 (60.0) | 72 (55.8) | ||
| cTNM stage (AJCC8th) | 0.78 | ||||
| I | 81 (31.3) | 38 (29.3) | 43 (33.3) | ||
| II | 68 (26.3) | 35 (26.9) | 33 (25.6) | ||
| III | 110 (42.5) | 57 (43.8) | 53 (41.1) | ||
| pT stage (AJCC8th) | 0.59 | ||||
| T1 | 86 (33.2) | 39 (30.0) | 47 (36.4) | ||
| T2 | 32 (12.4) | 19 (14.6) | 13 (10.1) | ||
| T3 | 91 (35.1) | 48 (36.9) | 43 (33.3) | ||
| T4a/T4b | 50 (19.3) | 24 (18.5) | 26 (20.2) | ||
| pN stage (AJCC8th) | 0.94 | ||||
| N0 | 110 (42.5) | 52 (40.0) | 58 (45.0) | ||
| N1 | 51 (19.7) | 27 (20.8) | 24 (18.6) | ||
| N2 | 43 (16.6) | 23 (17.7) | 20 (15.5) | ||
| N3 | 55 (21.2) | 28 (21.5) | 27 (20.9) | ||
| pTNM stage (AJCC8th) | 0.77 | ||||
| I | 95 (36.7) | 46 (35.7) | 49 (38.0) | ||
| II | 70 (27.0) | 34 (26.2) | 36 (27.9) | ||
| III | 94 (36.3) | 50 (38.5) | 44 (34.1) | ||
| Adjuvant chemotherapy | 0.65 | ||||
| No | 102 (39.4) | 53 (40.8) | 49 (38.0) | ||
| Yes | 157 (60.6) | 77 (59.2) | 80 (62.0) | ||
| No. of non-fluorescent station | 0.09 | ||||
| ≤1 | 79 (30.5) | 40 (30.8) | 39 (30.2) | ||
| 2 | 67 (25.9) | 29 (22.3) | 38 (29.5) | ||
| 3–4 | 85 (32.8) | 41 (31.5) | 44 (34.1) | ||
| >5 | 28 (10.8) | 20 (15.4) | 8 (6.2) | ||
Abbreviations: SMA: submucosal approach; SSA: subserosal approach; AJCC, American Joint Committee on Cancer; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); ECOG, Eastern Cooperative Oncology performance status; cT, clinical T; cN, clinical N; pT, pathological T; pN, pathological N.